Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer.

Autor: Yao CD; Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA., Davis KL; Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, CA, USA. kardavis@stanford.edu.; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. kardavis@stanford.edu.

Publikováno v: Cancer metastasis reviews [Cancer Metastasis Rev] 2024 Dec 03; Vol. 44 (1), pp. 15. Date of Electronic Publication: 2024 Dec 03.

α-Gal IgE Prevalence Patterns in the United States: An Investigation of 3000 Military Recruits.

Autor: Davis KL; Whispering Pines, North Carolina.

Publikováno v: Pediatrics [Pediatrics] 2024 Dec 01; Vol. 154 (Suppl 4), pp. S26.

Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M ⁺ diffuse midline gliomas.

Autor: Monje M; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. mmonje@stanford.edu.; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA. mmonje@stanford.edu.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. mmonje@stanford.edu.; Department of Neurosurgery, Stanford University, Stanford, CA, USA. mmonje@stanford.edu.; Department of Pathology, Stanford University, Stanford, CA, USA. mmonje@stanford.edu.; Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA. mmonje@stanford.edu., Mahdi J; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Majzner R; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Yeom KW; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.; Department of Neurosurgery, Stanford University, Stanford, CA, USA.; Division of Neuroradiology, Department of Radiology, Stanford University, Stanford, CA, USA., Schultz LM; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Richards RM; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Barsan V; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Song KW; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Kamens J; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Baggott C; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Kunicki M; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Rietberg SP; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Lim AS; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Reschke A; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Mavroukakis S; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Egeler E; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Moon J; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Patel S; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Chinnasamy H; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Erickson C; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Jacobs A; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Duh AK; Department of Neurosurgery, Stanford University, Stanford, CA, USA., Tunuguntla R; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Klysz DD; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Fowler C; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Green S; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA., Beebe B; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Carr C; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Fujimoto M; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Brown AK; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Petersen AG; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., McIntyre C; Cellular Therapy Facility, Stanford Health Care, Palo Alto, CA, USA., Siddiqui A; Cellular Therapy Facility, Stanford Health Care, Palo Alto, CA, USA., Lepori-Bui N; Cellular Therapy Facility, Stanford Health Care, Palo Alto, CA, USA., Villar K; Cellular Therapy Facility, Stanford Health Care, Palo Alto, CA, USA., Pham K; Cellular Therapy Facility, Stanford Health Care, Palo Alto, CA, USA., Bove R; Cellular Therapy Facility, Stanford Health Care, Palo Alto, CA, USA., Musa E; Cellular Therapy Facility, Stanford Health Care, Palo Alto, CA, USA., Reynolds WD; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Kuo A; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Prabhu S; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Rasmussen L; Department of Pediatrics, Division of Pediatric Critical Care Medicine, Stanford University, Stanford, CA, US., Cornell TT; Department of Pediatrics, Division of Pediatric Critical Care Medicine, Stanford University, Stanford, CA, US., Partap S; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA., Fisher PG; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA., Campen CJ; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA., Grant G; Department of Neurosurgery, Stanford University, Stanford, CA, USA., Prolo L; Department of Neurosurgery, Stanford University, Stanford, CA, USA., Ye X; Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD, USA., Sahaf B; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Davis KL; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Feldman SA; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Ramakrishna S; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA. ramakrs@stanford.edu.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. ramakrs@stanford.edu., Mackall C; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA, USA. cmackall@stanford.edu.; Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. cmackall@stanford.edu.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. cmackall@stanford.edu.; Division of Stem Cell Transplantation and Cell Therapy, Department of Medicine, Stanford University, Stanford, CA, USA. cmackall@stanford.edu.

Publikováno v: Nature [Nature] 2024 Dec; Vol. 636 (8043), pp. E6.

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

Autor: Weber J; Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Grossman School of Medicine, NYU Langone, New York, NY 10016, United States., Haque W; Department of Medicine, NYU Grossman School of Medicine, NYU Langone, New York, NY 10016, United States., Markovic SN; Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN 55905, United States., Salama AKS; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, United States., Mehmi I; The Angeles Clinic and Research Institute, Cedars Sinai, Los Angeles, CA 90025, United States., Sullivan RJ; Center for Melanoma, Massachusetts General Hospital, Boston, MA 02114, United States., Najjar YG; Clinical and Translational Research Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232, United States., van Akkooi ACJ; Melanoma Surgical Oncology, Melanoma Institute Australia, Wollstonecraft, Sydney, NSW 2065, Australia.; Faculty of Medicine and Health, University of Sydney, Camperdown, Sydney, NSW 2050, Australia.; Department of Melanoma and Soft Tissue Sarcoma, Division of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands., Menzies AM; Faculty of Medicine and Health, University of Sydney, Camperdown, Sydney, NSW 2050, Australia.; Medical Oncology, Melanoma Institute Australia, Wollstonecraft, Sydney, NSW 2065, Australia.; Medical Oncology, Royal North Shore Hospital, Northern Sydney Cancer Centre, St Leonards, NSW 2065, Australia.; Department of Cancer Medicine, Mater Hospital, North Sydney, NSW 2060, Australia., Long GV; Faculty of Medicine and Health, University of Sydney, Camperdown, Sydney, NSW 2050, Australia.; Medical Oncology, Melanoma Institute Australia, Wollstonecraft, Sydney, NSW 2065, Australia.; Medical Oncology, Royal North Shore Hospital, Northern Sydney Cancer Centre, St Leonards, NSW 2065, Australia.; Medical Oncology, Mater Hospital, North Sydney, NSW 2060, Australia., Taylor AM; Medical Oncology, Melanoma Institute Australia, Wollstonecraft, Sydney, NSW 2065, Australia., Haanen J; Division of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands.; Medical Oncology (Service d'oncologie médicale), Centre Hospitalier Universitaire Vaudois (CHUV), 1005 Lausanne, Switzerland., Zijlker LP; Division of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands., Davis KL; Medical Oncology, Royal North Shore Hospital, Northern Sydney Cancer Centre, St Leonards, NSW 2065, Australia., Karanth S; Real-World Data and Analytics, RTI Health Solutions, Research Triangle Park, NC 27709, United States., Norton D; Melanoma US Medical Team, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, United States., Connolly L; Real World Evidence Solutions, CONEXTS, Novartis Ireland Ltd., Dublin 4, D04 NN12, Ireland.

Publikováno v: The oncologist [Oncologist] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.

Suggested Screening Criteria for Gardnerella vaginalis Based on Established Risk Factors.

Autor: Sara A; Rheumatology, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA., Ramanujam A; Rheumatology, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA., Ram D; Rheumatology, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA., Davis KL; Microbiology, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA., Nagy S; Rheumatology, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA., Kesselman MM; Rheumatology, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, USA.

Publikováno v: Cureus [Cureus] 2024 Oct 21; Vol. 16 (10), pp. e72036. Date of Electronic Publication: 2024 Oct 21 (Print Publication: 2024).